Aytu BioPharma Statistics

Total Valuation

Aytu BioPharma has a market cap or net worth of GBP 8.24 million. The enterprise value is 6.69 million.

Market Cap	8.24M
Enterprise Value	6.69M

Important Dates

The next estimated earnings date is Thursday, February 13, 2025.

Earnings Date	Feb 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+39.29%
Shares Change (QoQ)	+61.92%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	4.39M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 0.99, with an EV/FCF ratio of -3.58.

EV / Earnings	-1.43
EV / Sales	0.10
EV / EBITDA	0.99
EV / EBIT	n/a
EV / FCF	-3.58

Financial Position

The company has a current ratio of 0.99, with a Debt / Equity ratio of 0.61.

Current Ratio	0.99
Quick Ratio	0.71
Debt / Equity	0.61
Debt / EBITDA	2.17
Debt / FCF	-7.27
Interest Coverage	-0.32

Financial Efficiency

Return on equity (ROE) is -23.48% and return on invested capital (ROIC) is -1.87%.

Return on Equity (ROE)	-23.48%
Return on Assets (ROA)	-0.72%
Return on Invested Capital (ROIC)	-1.87%
Return on Capital Employed (ROCE)	-2.63%
Revenue Per Employee	583,414
Profits Per Employee	-45,717
Employee Count	102
Asset Turnover	0.64
Inventory Turnover	2.06

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -37.73% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-37.73%
50-Day Moving Average	1.60
200-Day Moving Average	2.41
Relative Strength Index (RSI)	50.93
Average Volume (20 Days)	254

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.64

Income Statement

In the last 12 months, Aytu BioPharma had revenue of GBP 59.51 million and -4.66 million in losses. Loss per share was -1.20.

Revenue	59.51M
Gross Profit	40.49M
Operating Income	-1.07M
Pretax Income	-3.81M
Net Income	-4.66M
EBITDA	4.79M
EBIT	-1.07M
Loss Per Share	-1.20

Full Income Statement

Balance Sheet

The company has 15.00 million in cash and 13.57 million in debt, giving a net cash position of 1.43 million.

Cash & Cash Equivalents	15.00M
Total Debt	13.57M
Net Cash	1.43M
Net Cash Per Share	n/a
Equity (Book Value)	22.25M
Book Value Per Share	3.62
Working Capital	-383,495

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.77 million and capital expenditures -101,470, giving a free cash flow of -1.87 million.

Operating Cash Flow	-1.77M
Capital Expenditures	-101,470
Free Cash Flow	-1.87M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 68.03%, with operating and profit margins of -1.80% and -7.84%.

Gross Margin	68.03%
Operating Margin	-1.80%
Pretax Margin	-6.40%
Profit Margin	-7.84%
EBITDA Margin	8.05%
EBIT Margin	-1.80%
FCF Margin	n/a

Dividends & Yields

Aytu BioPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-39.29%
Shareholder Yield	-39.29%
Earnings Yield	-56.61%
FCF Yield	-22.67%

Stock Splits

The last stock split was on January 6, 2023. It was a reverse split with a ratio of 0.05.

Last Split Date	Jan 6, 2023
Split Type	Reverse
Split Ratio	0.05

Scores

Aytu BioPharma has an Altman Z-Score of -3.1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.1
Piotroski F-Score	n/a